Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for Rosacea (Chongqing Medical University)
ChiCTR2500096227Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in rosacea, sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: VISIA red area value and Symptom score (CEA and clinical symptoms). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
03
Conditions
rosacea
Beyond the preview
Go deeper on ChiCTR2500096227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096227.